Tag: MSI

(UroToday.com) The 2023 Society of Urologic Oncology (SUO) annual meeting held in Washington, D.C. between November 28th and December 1st, 2023, was host to a prostate cancer course. Dr. Alan Bryce provided an overview of the use and application of serial next generation sequencing (NGS) in the castrate-resistant prostate cancer disease…

WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. 2023/10/18. covid19.who.int/. Accessed 18 Oct 2023. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020;55:105955. doi.org/10.1016/j.ijantimicag.2020.105955. Article  CAS  PubMed  PubMed Central  Google Scholar …

Selinexor did not show a clinically meaningful improvement in the general study population. Maintenance selinexor (Xpovio) showed a significant progression-free survival (PFS) benefit compared with placebo in a subgroup of patients with TP53 wild-type advanced/recurrent endometrial cancer, according to findings from the phase 3 ENGOT-EN5/GOG-3055/SIENDO trial (NCT03555422).1,2 Data from the…

why genetics of neuromuscular disorders important? 4 answers what is the New Generation of Revolutionary Sequencing Technology Based on Semiconductor Chips 4 answers what is the purpose of fertilisation check in IVF 3 answers What are the limitations of challenge tests for genomic prediction? 4 answers What is the role…

Maintenance therapy with selinexor (Xpovio) improved progression-free survival (PFS) compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer, regardless of microsatellite instability (MSI) status, according to long-term follow-up data from the phase 3 ENGOT-EN5/GOG-3055/SIENDO trial (NCT03555422)presented at the 2023 IGCS Annual Global Meeting.1 At a median…

how to get ER, PR and HER2 data from TCGA BRCA 2 Hi I have dowloaded the BRCA data from TCGA using TCGABiolinks I have done this: BRCARnaseqSE <- GDCprepare(query.a, directory = “BRCA_all”) sample.info <- SummarizedExperiment::colData(BRCARnaseqSE) Now I want to get data on ER, PR and HER2 – positive, negative…

CHICAGO, November 15, 2023–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor, and the Molecular Diagnostics Services Program (MolDx) has approved coverage for Tempus|xT, Tempus’ 648-gene DNA sequencing panel, for use in solid tumor and hematologic malignancies, performed in Tempus’…

Cash runway extended through multiple data readouts and into Q1 of calendar 2025 MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1 portion of the ABILITY-1 Study including 100% and 70% reduction of target lesions in pancreatic and melanoma cancer patients, respectively Four-year follow-up…

The mystery of the ‘black box’ at the MacBook event. What is that object? On October 30th, during the latter part of Apple’s new MacBook Pro unveiling event, a black machine box connected to the MacBook was briefly captured on camera. The presenter at the event was discussing the speed…

NATICK, Mass., Nov. 8, 2023 /PRNewswire/ — Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City,…

GSK has announced positive results from a late-stage trial of its PD-1 inhibitor Jemperli (dostarlimab) plus chemotherapy in adults with primary advanced or recurrent endometrial cancer. The phase 3 RUBY trial has been evaluating Jemperli plus standard-of-care chemotherapy (carboplatin and paclitaxel), followed by Jemperli as a single agent, compared to…

Hedrick, S. M., Cohen, D. I., Nielsen, E. A. & Davis, M. M. Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature 308, 149–153 (1984). Article  CAS  PubMed  Google Scholar  Yanagi, Y. et al. A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains….

SHANGHAI, Oct. 25, 2023 /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient in Europe has been dosed in the international multi-centre phase 3 clinical trial (NCT05353257) of the company’s self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination with chemotherapy and concurrent radiotherapy in patients with limited-stage small cell lung…

SHANGHAI, Oct. 25, 2023 /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient in Europe has been dosed in the international multi-centre phase 3 clinical trial (NCT05353257) of the company’s self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination with chemotherapy and concurrent radiotherapy in patients with limited-stage small cell lung…

Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma Details Category: Antibodies Published on Thursday, 19 October 2023 13:34 Hits: 279 Subcutaneous nivolumab demonstrates noninferior pharmacokinetics (co-primary endpoints) and objective response rate (key secondary endpoint) compared…

Paired tumor and normal DNA samples from 30 patients were subjected to WES at four ZPM laboratories with subsequent data analysis performed at five ZPM bioinformatic institutions (Fig. 1). DNA was originally derived from fresh-frozen samples that had been analyzed by WES within the multicenter MASTER (Molecularly Aided Stratification for…

PHF5A expression analysis Figure 1A demonstrated that PHF5A expression level was compared between tumor and corresponding normal tissues using TIMER2 tool. As compared to normal tissues, PHF5A expression was considerably elevated in Bladder urothelial carcinoma (BLCA), Breast invasive carcinoma (BRCA), Cholangiocarcinoma (CHOL), Colon adenocarcinoma (COAD), Esophageal carcinoma (ESCA), Head and neck…

Location & Details 575 Walter Library and online About This Event:  In this tutorial, we will give an overview of the Agate cluster resources, the newest high performance computing cluster at MSI. We will walk through examples that use SLURM job arrays, as well as the main two ways to…

Global clinical results A total of 50,723 M. tuberculosis isolates with WGS and drug susceptibility test data from 64 countries were analysed, and encompassed all major lineages (L4 48.3%, L2 27.6%, L3 11.8%, L1 9.1%) (Table 1, Fig. 1B). Lineage 2.2.1 (Beijing strain-type) is the most prevalent in four of six…

The cyclic GMP-AMP synthase(cGAS)-stimulator of interferon genes(STING)pathway is one of the important intracellular signaling pathways responsible for the recognition of exogenous DNA and subsequent induction of type Ⅰ interferon responses. Interestingly, in recent years, the importance of the cGAS-STING pathway in promoting anti-tumor immune responses has been highlighted. Decreased expression…

Key Points Question  How does the efficacy and safety profile of tislelizumab compare with that of sorafenib as first-line treatment among patients with unresectable hepatocellular carcinoma (HCC)? Findings  In this phase 3 randomized clinical trial of 674 patients with HCC, tislelizumab demonstrated overall survival noninferiority compared with sorafenib, with numerically…

This tutorial covers the process of handling bulk RNAseq data with command line tools. Attendees will learn the structure of a “standard” bulk RNAseq analysis workflow and the names of commonly used tools to process the data. We will cover the setup and use of a command line MSI-developed analytical…

PRINCETON, N.J.–(BUSINESS WIRE)– Bristol-Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -77T trial met its primary endpoint of improved event-free survival (EFS) as assessed by Blinded Independent Central Review (BICR) in patients with resectable stage IIA to IIIB non-small cell lung cancer (NSCLC). In a prespecified interim analysis,…

Ritu Salani, MD, MBA Gynecologic Oncologist UCLA Health Los Angeles, CA CASE SUMMARY August 2021 A 64-year-old postmenopausal woman presented with abnormal uterine bleeding lasting 4 months. She noted that she underwent menopause at 55 years of age. She is a widow, has no children, and lives alone. Medical history:…

Circulating tumor DNA(ctDNA) status at the time of postoperative minimal residual disease (MRD) is a prognostic factor of recurrence for patients with radically resected stage II to IV colorectal cancer (CRC). Standard management calls for adjuvant chemotherapy for all patients following surgical resection; however, investi- gators have sought to refine…

I have a dataframe from a csv file with metadata from cancer tumors (age, sex at birth, tumor location, treatment type, etc). I would like to plot this information like the following figure: enter image description here With the tumor.ID on the x-axis and each metadata category on the x-axis,…

Patient characteristics In our analysis, we included patients with biliary tract cancer and available comprehensive molecular characterization data from five Austrian cancer centers. The data cut-off date was September 2022 (Fig. 1). Figure 1 Trial design: Flow chart depicting patient allocation. In total, the molecular profile of 159 patients with biliary…

Nokia Corporation (NOK Quick QuoteNOK – Free Report) recently unveiled AVA Data suite on Google Cloud, the cloud platform of Alphabet Inc. (GOOGL Quick QuoteGOOGL – Free Report) , to augment the development of software solutions with advanced AI-ML capabilities. The AVA Data suite is a comprehensive collection of readily…

Cholangiocarcinoma is an aggressive malignant tumor originating from the biliary tract and can be divided into three subtypes based on anatomical location: intrahepatic cholangiocarcinoma, perihepatic cholangiocarcinoma, and distal cholangiocarcinoma [1]. Although progress has been made in the field of cholangiocarcinoma treatment in recent years, cholangiocarcinoma mortality remains high [2]. Although…

The PositionRoche Sequencing Solutions (RSS), a business within Roche Diagnostics, focused on developing a disruptive Next-Generation Sequencing (NGS) platform along with a portfolio of reagents, assays and informatics solutions for multiple disease areas. We are looking for a Principal Bioinformatics Scientist in the NGS Algorithms and Applications team to support…

TCGAbiolinks MSI data 0 Hi! I am trying to use this code to access Microsatellita data: query <- GDCquery(project = “TCGA-COAD”, data.category = “Other”, legacy = TRUE, access = “open”, data.type = “Auxiliary test”, barcode = c(“TCGA-AD-A5EJ”,”TCGA-DM-A0X9″)) from TCGAbiolinks help documents, but I have this error message: “Error in checkDataCategoriesInput(project,…

Job Description About the Job The Research Informatics (RI) Bioinformatics group within the University of Minnesota Supercomputing Institute (MSI) is hiring a full-time Bioinformatics Analyst to support research for the Department of Microbiology and Immunology (MI) at the University of Minnesota. The analyst in this position will conduct cutting-edge bioinformatics…

In this competitive world of technology, Machine Learning and Artificial Intelligence technologies have emerged as a breakthrough for developing advanced AI applications like image recognition, natural language processing, speech translation, and more. However, developing such AI-powered applications would require massive amounts of computational power far beyond the capabilities of CPUs…

Background Effective treatment options are limited for patients (pts) with refractory metastatic colorectal cancer (mCRC). Fruquintinib (F), a highly selective, potent, oral tyrosine kinase inhibitor of VEGFR-1, -2, and -3, was approved in China in the 3L+ mCRC setting based on results from the FRESCO trial (NCT02314819). FRESCO-2 (NCT04322539) evaluated…

About the Job The Research Informatics (RI) Bioinformatics group within the University of Minnesota Supercomputing Institute (MSI) is hiring a full-time Bioinformatics Analyst to support research for the Department of Microbiology and Immunology (MI) at the University of Minnesota. The analyst in this position will conduct cutting-edge bioinformatics analyses in…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided an update on the Phase 3 LEAP-010 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, as a first-line treatment for patients…

NVIDIA is absolutely dominating the AI conversation right and for good measure – their GPUs perform out-of-the-box and are a top choice for professionals and businesses that want to dabble in consumer AI. But just this week, both Intel and AMD optimized their software stacks to get massive speedups in…

Recent updates to the National Comprehensive Cancer Network (NCCN) guidelines for the evaluation and management of patients with biliary tract cancers (BTCs) (gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma) were published in July 2023 in the Journal of the NCCN (JNCCN).[1] Select recommendations for molecular testing and for systemic therapy…

image: Genomic landscape of schistosomiasis-associated colorectal cancer. (A) Genetic characteristics of the SA-CRC. The number of mutations, the tumor mutation burden, the estimated MSI scores, and the predicted number of neo-epitopes of each sample were present. (B) Mutational landscape of recurrently mutated genes in SA-CRCs. Red arrow corresponds to the known…

In a study published in the journal Genes & Diseases, researchers from Naval Medical University and Soochow University conducted an in-depth investigation into the genomic landscape of schistosomiasis-associated colorectal cancer (SA-CRC). By utilizing whole exome sequencing on tumor tissues and their non-tumor counterparts obtained from thirty SA-CRC patients diagnosed at…

We are searching for a persistent Principal Scientist II Bioinformatics to join our energetic team at F. Hoffmann-La Roche Ltd in Mississauga, ON.Growing your career as a Full Time Principal Scientist II Bioinformatics is an incredible opportunity to develop key skills.If you are strong in leadership, critical thinking and have…

Jubilee Brown, MD Professor of Gynecologic Oncology Atrium Health Levine Cancer Institute Charlotte, NC CASE SUMMARY In August 2021, a 64-year-old postmenopausal woman presented with abnormal uterine bleeding lasting 4 months. ​She underwent menopause at 55 years of age. She is a widow, has no children, and lives alone​. She had…

In a recent article published in the Biologics Journal, researchers examined de-identified clinical data to identify gene fusions by next-generation deoxy- and ribonucleic acids (DNA and RNA) sequencing to understand their relationship with observed pathologies in a diverse population of cancer patients. Study: Precision Medicine in a Community Cancer Center: Pan-Cancer DNA/RNA…

Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635–48. Article  CAS  PubMed  Google Scholar  Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. Article  PubMed  Google Scholar  Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat…

The Research Informatics (RI) Bioinformatics group within the University of Minnesota Supercomputing Institute (MSI) is hiring a full-time Bioinformatics Analyst to support basic biomedical and applied clinical genetic research for the Department of Laboratory Medicine and Pathology (LM&P) at the University of Minnesota. The analyst in this position will…

In an interview with CancerNetwork®, Brian Slomovitz, MD, MS, FACOG, spoke about “unprecedented” findings from the phase 3 RUBY trial (NCT03981796) that supported the FDA approval of dostarlimab (Jemperli) plus chemotherapy as a treatment for patients with primary advanced or recurrent mismatch repair deficient (dMMR) or microsatellite instability–high (MSI-H) endometrial…

AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy U.S. Food and Drug Administration approval represents a potential significant…

Chula Vista scolds Republic Service for lingering strike, may sever ties with waste hauler. Public Safety. County Board of Supervisors approves ordinance to outlaw ghost guns. San Diego City Council approves school rebuild plan. New proposal would transform much of northeast Mission Bay into marshland. Two people shot, deputies searching…

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer Details Category: Antibodies Published on Friday, 28 July 2023 17:17 Hits: 194 KEYTRUDA® (pembrolizumab) plus chemotherapy before surgery significantly improved pCR rate compared to neoadjuvant placebo plus…

TTTest July 28, 2023, 12:02pm 1 Machine learning newbie here, stuck on the first step of learning PyTorch of installing CUDA. I’ve been trying to get CUDA working on my system for the past day to no avail. I’ve created multiple environments then tried installing pytorch using the below config…

July 28, 2023 6:45 am ET KEYTRUDA® (pembrolizumab) plus chemotherapy before surgery significantly improved pCR rate compared to neoadjuvant placebo plus chemotherapy KEYNOTE-756 is the first positive Phase 3 study with an immunotherapy regimen to demonstrate a statistically significant improvement in pCR rate in the neoadjuvant setting for this patient…

About the Phase 3 XPORT-EC-042 Study Trial Name: A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma ClinicalTrials.gov Identifier: NCT05611931 Sponsor: Karyopharm Therapeutics Inc. Recruitment Contact: Karyopharm Medical Information, (888) 209-9326, clinicaltrials@karyopharm.com Completion…

In recent years, different investigations in the area of multi-center genomics research from gene to systems level and next-generation sequencing, clarified the various mechanisms specifically involved in the tumor progression [29]. This study used bioinformatics analysis to further investigate the genes involved in GC pathogenesis. In addition, the current study…

Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer Details Category: Antibodies Published on Wednesday, 19 July 2023 18:10 Hits: 115 KEYTRUDA® (pembrolizumab) plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus…

Job Details Level:    Experienced Job Location:    Waltham MA – Waltham, MA Position Type:    Full Time Education Level:    Graduate Degree Salary Range:    Undisclosed Travel Percentage:    Up to 10% Job Shift:    Day Job Category:    Research Description Principal Bioinformatics Engineer   The Opportunity Exosome Diagnostics, a Bio-Techne brand (NASDAQ: TECH), is a global…

The following is a summary of the “Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma,” published in the March 2023 issue of Hepatology by Kendre, et al. For precision oncology in gastrointestinal malignancies, intrahepatic cholangiocarcinoma (iCCA) has emerged as a “role model” in recent years. However, its genetic…

Background: Hepatocellular carcinoma (HCC) has a poor long-term prognosis. The competition of circular RNAs (circRNAs) with endogenous RNA is a novel tool for predicting HCC prognosis. Based on the alterations of circRNA regulatory networks, the analysis of gene modules related to HCC is feasible. Methods: Multiple expression datasets and RNA…

Article 07/06/2023 2 contributors Feedback In this article APPLIES TO: Azure CLI ml extension v2 (current) Python SDK azure-ai-ml v2 (current) Learn how to create a compute instance in your Azure Machine…

The Position Roche Sequencing Solutions (RSS), a business within Roche Diagnostics, focused on developing a disruptive Next-Generation Sequencing (NGS) platform along with a portfolio of reagents, assays and informatics solutions for multiple disease areas. We are looking for a Principal Bioinformatics Scientist in the NGS Algorithms and Applications team to…

The Position Roche Sequencing Solutions (RSS), a business within Roche Diagnostics, focused on developing a disruptive Next-Generation Sequencing (NGS) platform along with a portfolio of reagents, assays and informatics solutions for multiple disease areas. We are looking for a Principal Bioinformatics Scientist in the NGS Algorithms and Applications team to…

Cancer immunotherapies have transformed the treatment landscape of many tumor types by stimulating the body’s mechanisms of targeting cancer cells. The efficacy of immune checkpoint inhibitors (ICIs) can vary widely between different tumor types based on immunogenicity and other factors—even patients with the same disease may respond very differently to…

Bao X, Shi R, Zhao T, Wang Y, Anastasov N, Rosemann M et al (2021) Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC. Cancer Immunol Immunother 70(1):189–202 Article  CAS  PubMed  Google Scholar  Becht E, McInnes L, Healy J,…

FDA Approves Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma The FDA has granted accelerated approval to enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.1 The regulatory decision was supported by data from the…

CASE SUMMARY A 75-year-old man presented with intermittent left hip pain and his physical exam was unremarkable expect for a prostate nodule on a rectal exam. The patient had an ECOG performance score of 1 and a prostate-specific antigen (PSA) of 16.2 ng/mL with a transrectal ultrasound scan (TRUS) and…

RAHWAY, N.J., June 20, 2023–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the Phase 3 KEYNOTE-585 trial, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as neoadjuvant treatment, followed by adjuvant treatment with KEYTRUDA plus chemotherapy, then KEYTRUDA…

You may have heard of the enzyme-linked immunosorbent assay, more commonly known as the ELISA test, which is used to measure molecules like antibodies, antigens and proteins in biological samples. Used to diagnose infections caused by human immunodeficiency viruses (HIV) as well as to detect the pregnancy hormone human chorionic…

The Position Roche Sequencing Solutions (RSS), a business within Roche Diagnostics, focused on developing a disruptive Next-Generation Sequencing (NGS) platform along with a portfolio of reagents, assays and informatics solutions for multiple disease areas. We are looking for a Principal Bioinformatics Scientist in the NGS Algorithms and Applications team to…

FDA Approves Novel Cyclosporine for Dye Eye Disease The FDA has approved Novaliq’s Vevye (cyclosporine) 0.1% to treat patients with dry eye disease. Vevye (which had development name CyclASol) is a water-free, preservative-free solution based on EyeSol technology. Cyclosporine is not water-soluble, but the EyeSol excipient perfluorobutylpentane allows for improved bioavailability…

The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application for dostarlimab in combination with chemotherapy for the treatment of adults with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)-blocking antibody. The sBLA was supported by…

The Position Roche Sequencing Solutions (RSS), a business within Roche Diagnostics, focused on developing a disruptive Next-Generation Sequencing (NGS) platform along with a portfolio of reagents, assays and informatics solutions for multiple disease areas. We are looking for a Principal Bioinformatics Scientist in the NGS Algorithms and Applications team to…

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA alone The DMFS results, a key secondary endpoint of the Phase 2b KEYNOTE-942 study, will be presented at the 2023 American Society of Clinical…

Patients treated with dual immunotherapy-based combination demonstrate sustained clinical benefits after four years vs. chemotherapy alone, with magnitude of benefit more pronounced amongst patient subgroups with high unmet needs Late-breaking data to be presented during the 2023 American Society of Clinical Oncology Annual Meeting PRINCETON, N.J., June 04, 2023–(BUSINESS WIRE)–Bristol…

Health-related quality-of-life (HRQOL) outcomes from the phase 3 ENGOT-EN6/GOG3031/RUBY trial (NCT03981796) shows patients with primary advanced or recurrent endometrial cancer were not adversely affected by the combination of dostarlimab-gxly (Jemperli) and carboplatin/paclitaxel (CP) more so than chemotherapy alone, according to data presented at the 2023 ASCO Annual Meeting.1 Patient reported…

An analysis of patient-reported outcomes (PROs) from the phase 3 ENGOT-EN6/GOG3031/RUBY trial (NCT03981796) suggest that dostarlimab-gxly (Jemperli) does not negatively affect health-related quality-of-life (HRQOL) outcomes when used in combination with carboplatin/paclitaxel (CP) in patients with primary advanced or recurrent endometrial cancer. Findings were presented during the 2023 American Society of…

PRINCETON, N.J.–(BUSINESS WIRE)–Jun 4, 2023– Bristol Myers Squibb (NYSE: BMY) today announced four-year follow-up results from the Phase 3 CheckMate -9LA trial demonstrating durable, long-term survival benefits with Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy compared to four cycles of chemotherapy alone in previously untreated patients with…

Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer Details Category: Antibodies Published on Sunday, 04 June 2023 15:16 Hits: 87 Patients treated with dual immunotherapy-based combination demonstrate…

Labcorp has recently made a groundbreaking announcement that its new liquid biopsy test, Plasma Focus, is now available for patients who are suffering from advanced or metastatic solid tumors. The test is a laboratory-developed test (LDT) that utilizes Next Generation Sequencing-based technology to detect genomic sequence mutations in 33 genes…

My colon cancer patients are getting younger. The diagnoses are happening just as some of these individuals are embarking on their plans for life, while others are in the crucial midst of parenthood. Given this, the tragedy of their cancers feels exponentially greater. This youthful trend in my clinic is…

Superpowered by AI, Newest GPUs Provide 2x the Horsepower of Latest Gaming Consoles NVIDIA today announced the GeForce RTX™ 4060 family of GPUs, with two graphics cards that deliver all the advancements of the NVIDIA® Ada Lovelace architecture — including DLSS 3 neural rendering and third-generation ray-tracing technologies at high…

In this third episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, of Columbia University Herbert Irving Comprehensive Cancer Center, discusses testing guidance for identifying Lynch syndrome. Universal testing with MSI or immunohistochemistry [IHC] in all newly diagnosed colorectal cancer [CRC] is a firm guideline, and…

Center for Biomedical Research, Health Research Organization, National Research and Innovation Agency (BRIN), Cibinong, West Java, Indonesia Correspondence: Frans Dany, Biomedical Research Center, Health Research Organization, Genomic Building, Cibinong Science Center, Jl. Raya Bogor No. 490, Cibinong, 16911, West Java, Indonesia, Email [email protected]; [email protected] Dear editor We are very interested…

We are looking to hire a resourceful Principal scientist bioinformatics to join our incredible team at Roche in Washington DC.Growing your career as a Full Time Principal scientist bioinformatics is an incredible opportunity to develop excellent skills.If you are strong in presentation, adaptability and have the right mindset for the…

Tempus on Monday announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) for its xT CDx sequencing test as a companion diagnostic. xT CDx is a 648-gene next-generation sequencing test (NGS) for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for…

xT CDx is the company’s first Premarket Approval from the FDA CHICAGO, May 01, 2023–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first Premarket Approval (PMA) application for its companion diagnostic test, xT CDx….

Hello everyone, I’m new to the community This is my first post, I have a problem on my laptop I have a beautiful laptop which is msi Morden 15 A5M with 5700U and its own iGPU There’s no other gpus, and I got two DDR4 3200 16G rams the system…

Design of this study In this study, we use 98 MAGs described previously from Guaymas Basin hydrothermal plumes (see Metagenomic datasets and model building in Methods) to understand metabolic interactions and evolution in hydrothermal systems (Refer Supplementary File S1 for the short name references used in this article). Both bacteria and archaea…

Typhoid GBD, Paratyphoid C. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis. 2019;19(4):369–81. Article  Google Scholar  Arndt MB, Mosites EM, Tian M, Forouzanfar MH, Mokhdad AH, Meller M, Ochiai RL, Walson JL. Estimating the burden of…

Adding immunotherapy to chemotherapy continues to be the standard treatment method for patients with endometrial cancer, regardless of disease stage, according to John Nakayama, MD. Recent data presented at the Society of Gynecologic Oncology (SGO) Annual Meeting may bring additional combinations to the armamentarium. The phase 3 NRG-GY018 study (NCT03914612)…

I am trying to use LAMMPS MPI for parallel computation in a single workstation having windows operating system. I have installed MPICH2 from the link www.mpich.org/static/downloads/1.4.1p1/mpich2-1.4.1p1-win-x86-64.msi.But when I was trying to run lammps from command prompt using the command linempiexec -np 4 lmp -in “input file”the system is showing the…

By Jo CavalloPosted: 4/18/2023 10:44:00 AM Last Updated: 4/18/2023 12:19:55 PM Black individuals are disproportionately affected by colorectal cancer. They have the highest rates of the disease of any racial or ethnic group in the United States, and are about 20% more likely to develop colorectal cancer and about 40%…

Background: FBXW7 is recognized as a critical tumor suppressor gene and a component of the ubiquitin-proteasome system, mediating the degradation of multiple oncogenic proteins, including c-MYC, Cyclin E, c-Jun, Notch, p53. Around 16% of colorectal cancer (CRC) patients carried FBXW7 somatic mutations, while a comprehensive characterization of FBXW7 somatic mutations…

Genomic profiling of circulating tumor DNA (ctDNA) with a large panel appeared feasible in a routine setting and helped to obtain relevant molecular information that could inform strategies with targeted therapies for patients with metastatic solid tumors, according to findings from the prospective PRISM study published in Annals of Oncology….

The PositionRoche Sequencing Solutions (RSS), a business within Roche Diagnostics, focused on developing a disruptive Next-Generation Sequencing (NGS) platform along with a portfolio of reagents, assays and informatics solutions for multiple disease areas. We are looking for a Principal Bioinformatics Scientist in the NGS Algorithms and Applications team to support…

Expression of IGFL2 in cancer According to the TIMER2.0 database results, the difference in IGFL2 expression between cancer and normal tissues was significant in most cancers, including BLCA, BRCA, CHOL, COAD, ESCA, GBM, HNSC, KIRC, KIRP, LIHC, LUAD, LUSC, SKCM, HNSC, STAD THCA, and UCEC, while IGFL2 expression was higher…

In collaboration with prominent biopharma companies and academic institutions, Biognosys will demonstrate the technological advances and versatility of the TrueDiscovery™, TrueTarget™, and TrueSignature™ proteomics platforms across the entire spectrum of oncology research and clinical development Proteoverse™ offers intuitive and interactive data visualization to make proteomics data more accessible and easily…

RAHWAY – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merck‘s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. LEAP-003: Merck and Eisai…

Differential expression of DDR1 between tumor and normal tissue samples To better understand DDR1 expression levels in various cancer types, we first performed a pan-cancer analysis of 33 cancers in the TCGA database. Excluding cancers without corresponding normal samples, significant differences in DDR1 expression were found between tumor and normal…

(RTTNews) – Merck (MRK) and Eisai Co., Ltd. announced that Phase 3 LEAP-003 trial and LEAP-017 trial failed to meet endpoint of overall survival (OS). The companies stated that Phase 3 LEAP-003 trial evaluating KEYTRUDA plus LENVIMA for the first-line treatment of adults with unresectable or metastatic melanoma did not…

Mosaic Therapeutics, Ltd has closed its $28 million series A funding round. The investment in this round was raised from Syncona Investment Management, Ltd, and Cambridge Innovation Capital. The company also announced the appointment of former Novartis Oncology SVP Brian Gladsden as CEO.  The Series A funding will be used to…

The FDA has granted full approval to pembrolizumab (Keytruda) for adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, according to a press release from Merck. “This…